TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06697015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pendulum Exercises
Description: In this group, 18 participants will perform pendulum exercises, which involve leaning forward and allowing the affected arm to hang down, swinging it gently in small circular or side-to-side motions. This exercise is designed to enhance shoulder mobility and promote relaxation of the rotator cuff muscles without straining the shoulder joint. The pendulum movement helps improve circulation and relieve tension in the shoulder area, making it a suitable intervention for individuals experiencing rotator cuff pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Punch Exercises
Description: In this group, 18 participants will engage in serratus punch exercises, focusing on strengthening the serratus anterior muscle. Participants will perform a punching motion by extending the arm forward while maintaining shoulder stability. This exercise activates the shoulder muscles to enhance scapular control, supporting the rotator cuff and improving overall shoulder function. The goal is to build strength in the stabilizing muscles, which can help alleviate pain and enhance mobility in participants suffering from rotator cuff issues.
Study: NCT06697171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 Not an ad disclosure
Description: Same social media post viewed as all other groups. @brandname in the narrative body of the social media post; #NotAnAd in the narrative body of the social media post

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 Basic Disclosure
Description: Same social media post viewed as all other groups. @brandname in the narrative body of the social media post; #ad in the narrative body of the social media post

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 3 Basic + Paid Partnership Disclosure
Description: Same social media post viewed as all other groups. COI disclosures include paid partnership in the header and a tag for the industry partner; @brandname and #ad immediately at the beginning of the narrative body of the social media post;~#ad and #sponsored at the bottom of the narrative body of the social media post.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No COI disclosure elements (i.e. no hashtags ). Only the @brandname is included within the narrative body of the social media post.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 4 Basic + Paid Partnership + Image label
Description: Same social media post viewed as all other groups. COI disclosures include paid partnership in the header and a tag for the industry partner; @brandname and #ad immediately at the beginning of the narrative body of the social media post; #ad and #sponsored at the bottom of the narrative body of the social media post; #ad (black text, white background) appears on the photo associated with the social media post
Study: NCT06697314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System
Description: Single Arm Study - Use of AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 for the treatment of acute pulmonary embolism
Study: NCT06697873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group: A
Description: 21 participants will receive both Rhythmical stabilization and closed chain kinetic exercise followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group B
Description: 21 participants will receive Rhythmical stabilization training program followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes.
Study: NCT06697574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis aimed at stress reduction and health of the oral mucosa
Description: * Induction.~* Hypnotic relaxation and escalating deepening of hypnotic trance.~* Suggestions for healing and wellness of the oral mucosa and for balanced and optimal performance of the immune system, tailoring metaphors and images based on interview with patients.~...the interior of the mouth is soft, healthy pink, intact and whole. It functions optimally as it should - enabling joyful eating and tasting, speaking with ease for any needed expression, any function of the mouth that needs to be used can be done so easily.~The immune system is very wise - it knows perfectly how to function in a balanced and harmonious way. Its wisdom enables it to act if the body needs defense and to standby and rest if it does not.~* Ego strengthening.~* Anchoring - using a predetermined mark selected by the patient.~* Dehypnotisation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: A short explanation about the psycho-neuro-immune system and its part in oral lichen planus

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: A short explanation about the psycho-neuro-immune system and its part in oral lichen planus
Study: NCT06696560

Intervention type: OTHER
Group type: OTHER
Intervention: Minimal Invasive Approaches in Aortic surgeries.
Description: Minimal Invasive Approaches For Aortic Valvular and Subvalvular Surgeries
Study: NCT06711978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirogabalin
Description: Participants will receive Mirogabalin at a dose of twice daily for 4 weeks to manage CIPN pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Participants will receive Duloxetine at a dose of once daily for 4 weeks to manage CIPN pain.
Study: NCT06712277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video training
Description: After the procedure, caregivers will be trained on tube care and patient feeding by demonstrating and performing the procedure on an iPad.
Study: NCT05562830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles
Study: NCT04308551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen
Description: Indobufen Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin Tablets
Study: NCT06378762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Exercise
Description: 30 minutes of running at an intensity corresponding to the heavy-domain (between the first and second ventilatory thresholds)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Exercise
Description: Combination of strength and power exercises Weeks 1-5 focus on building maximal strength Weeks 6-11 focus on maintaining maximal strength and improve muscle power

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Exercise
Description: Combining both strength and endurance training programs, with strength preceding endurance, incorporating a 20-min rest period between each modality
Study: NCT05696730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication intervention about sexuality in people with COPD
Description: COSY is a communication intervention which consists of one face to face counselling (75 min) and two 30-min telephone call counselling.~Patients assigned to the intervention group will get the COSY communication intervention with a special focus on the positive impact of sexuality on wellbeing plus specific motivation for physical activity. Together with the patient, a personalized re-enforcement instrument, the COSY-Compass, is elaborated to set individual goals and motivation for physical activity over the whole intervention period (3 months).~Participants will learn to understand the positive effect of regular physical activity on physical, mental, and cognitive wellbeing and a more fulfilling sex life as well as get inspiration about the spectrum and possible expressions and manifestations of caring and intimacy with oneself.
Study: NCT05359900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Pain neuroscience education lecture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Flag Education
Description: Red Flag education lecture
Study: NCT05339906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZOV.ai digital therapy candidate
Description: ZOV.ai is a novel auditory neuro modulating technology that leverages euphonic music tracks with broad-spectrum binaural beats to induce selective EEG spectral power changes to improve stuttering symptoms
Study: NCT06166082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active iTBS-DLPFC
Description: Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.
Study: NCT06462976

Intervention type: OTHER
Intervention: mechanical power calculation
Description: Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation

Intervention type: OTHER
Intervention: mechanical power calculation
Description: Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
Study: NCT05469958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia prevention bundle
Description: pre-warming of the patient for 10 minutes with forced air blankets before the surgery starts, which will be maintained during surgery and during the immediate postoperative period, the intravenous perfusions will be warmed up to 38 Celsius degree (ºC) and the environmental temperature will be controlled at 21 Celsius degree (ºC) during surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: the patient will be attended with textile blankets on patient demand
Study: NCT06030544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OA-enriched functional olive oil
Description: Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a functional olive oil enriched in Oleanolic acid (equivalent dose 30 mg/day OA) Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: commercial olive oil
Description: Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.
Study: NCT04370444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phallus Length Reducer
Description: Phallus Length Reducer

Intervention type: OTHER
Group type: OTHER
Intervention: Self-assessment of dyspareunia
Description: Use of a vaginal insert to self assess dyspareunia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-assessment of dyspareunia
Description: Use of a vaginal insert to self assess dyspareunia
Study: NCT06166082

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS-DLPFC
Description: The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
Study: NCT06250426

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-thickened oral nutritional supplement with a cooling sensation flavour
Description: Pre-thickened oral nutritional supplement (ONS) drink with cooling sensation flavour
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib under the guidance of MTB.
Study: NCT04444349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Coenzyme Q10 is a cardiovascular health supplement. It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. The ingredients in Coenzyme Q10 help regulate the body's production of free radicals, strengthen the arteries and heart, and reverse oxidation.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Standard Medical Therapy
Description: Patients only received standard medical therapy without CoQ10.
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying CKIT mutation will be administrated with imatinib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying CKIT mutation will be administrated with imatinib under the guidance of MTB.
Study: NCT03978117

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze dried Powder
Description: Freeze dried powder containing gluconasturtiin, which when added to a provided juice, will result in a target dose of up to 40 mg/day of 2-phenethyl isothiocyanate (PEITC). Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Freeze dried Powder
Description: Freeze dried powder containing gluconasturtiin, which when added to a provided juice, will result in a target dose of up to 40 mg/day of 2-phenethyl isothiocyanate (PEITC). Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Preparation
Description: Placebo powder added to a provided juice. Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Preparation
Description: Placebo powder added to a provided juice. Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125mg, 21/7 dosing schedule Patients with advanced rare tumours who failed to standard treatment following HR(+)/HER-2(-) will be administrated with palbociclib under the guidance of MTB.
Study: NCT04493333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Dehydroepiandrosterone
Description: This is a vaginally administered suppository steroid indicated for the treatment of moderate to severe dyspareunia, a frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause.
Study: NCT06250426

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pre-thickened oral nutritional supplement without a cooling sensation flavour
Description: Pre-thickened oral nutritional supplement (ONS) drink without cooling sensation flavour
Study: NCT04493333

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Polycarbophil Moisturizer
Description: This is an FDA cleared, over-the-counter personal lubricant for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. It is non-sterile, water-based, non-irritating, non-greasy, non-staining vaginal gel delivered as a long-lasting moisturizer for vaginal dryness.
Study: NCT06475183

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum
Description: Bouchard Belgian Dark Chocolate Probiotic Napolitains containing 10 billion CFUs of bifidobacterium longum daily for 6 weeks
Study: NCT04710303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 \[E1-, E2b-, E3-\] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 \[E1-, E2b-, E3-\] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 \[E1-, E2b-, E3-\] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 \[E1-, E2b-, E3-\] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.
Study: NCT05791630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the labour care guide (LCG)
Description: The labour care guide is a tool to be used for assessing labour progression and monitoring care in labour
Study: NCT06307366

Intervention type: OTHER
Intervention: No intervention will be used
Description: This is a qualitative study, no intervention will be used
Study: NCT06570265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GBR membrane
Description: GBR procedure is a technique often used in conjunction with dental implants to enhance the success and stability of the implant. This technique involves using barrier membranes to protect the bone graft or defect site from the rapid proliferation of surrounding soft tissues. In this clinical investigation resorbable, collagen membrane will be used.
Study: NCT04486677

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caring Cards Group
Description: Group of Veteran card-makers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caring Cards Recipients
Description: Group of Veteran card-recipients.
Study: NCT04876391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab
Study: NCT06381622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 30 mL Ropivacaine 5 mg/mL (= 150 mg Ropivacaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 30 mL Ropivacaine 5 mg/mL (= 150 mg Ropivacaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine epinephrine
Description: 20 mL Ropivacaine 5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg) / ml (= 100 mg Ropivacaine + 200 mg Lidocaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine epinephrine
Description: 20 mL Ropivacaine 5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg) / ml (= 100 mg Ropivacaine + 200 mg Lidocaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: 20 mL Ropivacaine 7,5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg)/mL (= 150 mg Ropivacaine + 200 mg Lidocaine)
Study: NCT05886127

Intervention type: DEVICE
Intervention: A novel hemostatic agent (Purastat®)
Description: A novel hemostatic agent (Purasta®) will be applied on cutted ampulla of Vater
Study: NCT06320366

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: The TMS Cool-B65 A/P coil on its placebo side delivers electrical stimulation to the scalp (e.g., mimicking sensations associated with real stimulation) but does not provide magnetic stimulation to the targeted cortical structure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TMS
Description: The TMS Cool-B65 A/P coil delivers magnetic stimulation to targeted cortical structure.
Study: NCT06452706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug conjugate (ADC).
Study: NCT06041880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive calf muscle stretching device
Description: Modified night splints will be used to passive stretch the calf muscle.
Study: NCT04703751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter
Description: Investigated device - the CIRCULATE Catheter will be introduced, using a standard radial or femoral access and a typical guiding catheter and typical coronary wire, first into the right coronary artery. After that the one dose of NTG (200µg) will be administered followed by a typical angiographic recording to visualize the vasodilatatory effect of the medication. Then CardioCell in doses of 10mln cells each (6.7mL) will be administered transcoronary to each of the coronary arteries (right coronary artery (RCA), LAD, left circumflex (Cx)). Angiography will be performed routinely before and after each product administration.
Study: NCT05492448

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. salivarius AP-32 and L. reuteri GL-104
Description: Subjects take one pack containing L. salivarius AP-32 and L. reuteri GL-104 twice daily after breakfast and dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri GL-104
Description: Subjects take one pack containing L. reuteri GL-104 twice daily after breakfast and dinner.